Paul Romesser, MD

MSK radiation oncologist Paul Romesser
LocationA pin, used as a metaphor for the concept of location. Locations Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. New Patient Appointments Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.
Phone iconAn icon showing a telephone. Phone Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

About Me

I am a radiation oncologist who has expertise in using advanced techniques to treat cancer. These include image-guided radiation therapy, intensity-modulated radiation therapy, stereotactic radiosurgery, and proton beam radiotherapy. I am also actively involved in cancer clinical trials. I work to take ideas developed in the lab and translate them into actual trials and treatments that can benefit people with cancer.

At Memorial Sloan Kettering, we approach treating cancer as a team. I work closely with surgical and medical oncologists, radiologists, and pathologists. I can confidently tell my patients that they will receive the best care in the world because of the team of experts that will support them every step of the way. I make sure all my patients are aware of who is on their care team, our individual roles, and how we work together to create a personalized treatment plan.

I also make sure my patients have a solid understanding of their diagnosis. I take time to explain how radiation therapy fits into treating their disease, as well as all the potential benefits and side effects. While many patients have concerns about radiation therapy, I hope that after meeting with me, they and their families feel reassured about what lies ahead. 

Clinical trials, in my opinion, offer patients an opportunity to get the most progressive cancer care available. I know that the decision to participate or not participate in a trial can make people anxious.  Ultimately the decision is a very personal one for patients and their families. I hope that by explaining the ins and outs of clinical trials, I can help guide my patients to make the right decision for them.

After patients leave my office, I hope that they feel that they have a strong advocate who will stop at nothing to ensure they are getting the best treatment. 

  • Clinical Expertise: Image-guided radiation therapy (IGRT); Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Radiosurgery (SRS), Proton Beam Radiotherapy (PBRT)
  • Languages Spoken: English
  • Education: MD, Boston University School of Medicine
  • Residencies: Radiation Oncology - Memorial Sloan Kettering Cancer Center


Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiotherapy and Oncology. 2016; 118(2):286-292. PMID 26867969.

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox, JL, Mah D, Garg, MK, Chang J, Lee NY. Proton beam re-irradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. International Journal of Radiation Oncology Biology, and Physics. 2016; 95(1):386-395. PMID: 27084656.

Romesser PB, Romanyshyn JC, Schupak KD, Setton J, Riaz N, Wolden SL, Gelblum DY, Sherman EJ, Kraus D, Lee NY. Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy.  Cancer. 2012; 118(24):6072-6078. PMID 22707358.

Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of Surgical Oncology. 2014; 110(4):375-382. PMID 24961938.

Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, Sherman EJ, Schoder H, Lee NY. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pretreatment 18F-fluorodeoxyglucose positron emission tomography scan. Oral Oncology. 2014; 50(9):802-808. PMID 25043882.

Visit PubMed for a full listing of Paul Romesser’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.